Abivax SA American Depositary Shares (ABVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.52 Million) by net assets ($429.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ABVX market cap overview for the company's overall valuation and market capitalisation.
Abivax SA American Depositary Shares - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Abivax SA American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abivax SA American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abivax SA American Depositary Shares ranked by their cash flow conversion efficiency. See Abivax SA American Depositary Shares (ABVX) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stantec Inc
TO:STN
|
0.035x |
|
Viper Energy Ut
NASDAQ:VNOM
|
0.047x |
|
Janus Henderson Group PLC
NYSE:JHG
|
0.041x |
|
Itissalat Al-Maghrib (IAM) S.A
F:MSPA
|
0.151x |
|
Suzhou Maxwell Technologies Co Ltd Class A
SHE:300751
|
0.005x |
|
Shandong Hualu Hengsheng Chemical Co Ltd
SHG:600426
|
0.026x |
|
Xpeng Inc
NYSE:XPEV
|
0.004x |
|
Beijing Huafeng Test & Control Technology Co Ltd
SHG:688200
|
0.020x |
Annual Cash Flow Conversion Efficiency for Abivax SA American Depositary Shares (2014–2025)
The table below shows the annual cash flow conversion efficiency of Abivax SA American Depositary Shares from 2014 to 2025. View ABVX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $455.01 Million | $-155.69 Million | -0.342x | +90.99% |
| 2024-12-31 | $40.58 Million | $-154.07 Million | -3.796x | -644.06% |
| 2023-12-31 | $196.01 Million | $-100.01 Million | -0.510x | +93.20% |
| 2022-12-31 | $7.19 Million | $-53.94 Million | -7.503x | -331.90% |
| 2021-12-31 | $25.93 Million | $-45.05 Million | -1.737x | -4.26% |
| 2020-12-31 | $17.90 Million | $-29.82 Million | -1.666x | -12.75% |
| 2019-12-31 | $18.59 Million | $-27.47 Million | -1.478x | -250.67% |
| 2018-12-31 | $34.66 Million | $-14.60 Million | -0.421x | -140.29% |
| 2017-12-31 | $48.18 Million | $-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | $56.72 Million | $-15.61 Million | -0.275x | -32.51% |
| 2015-12-31 | $71.77 Million | $-14.90 Million | -0.208x | -113.23% |
| 2014-12-31 | $33.94 Million | $-3.31 Million | -0.097x | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more